Drug · CHEMBL3545313
BEMPEDOIC ACID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. BEMPEDOIC ACID. Drugs and targets, record CHEMBL3545313. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3545313
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 6 of its 17 diseases, from ATC, DailyMed, EMA Human Drugs, FDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ACLY | ATP-citrate synthase | ATP-citrate synthase inhibitor | INHIBITOR | https://conductscience.org/library/genes/47 |
Source ChEMBL
Diseases17
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Hypercholesterolemia | Approval | EMA Human Drugs | 16 | 14 | https://conductscience.org/library/drugs?q=HP_0003124 |
| type 2 diabetes mellitus | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005148 |
| hyperlipidemia | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0021187 |
| cardiovascular disorder | Approval | ATC | 4 | 2 | https://conductscience.org/library/drugs?q=MONDO_0004995 |
| myocardial infarction | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005068 |
| inherited lipid metabolism disorder | Approval | EMA Human Drugs | 3 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002525 |
| acute coronary syndrome | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005542 |
| autosomal dominant polycystic kidney disease | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004691 |
| coronary atherosclerosis | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0021661 |
| hemorrhagic stroke | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0020921 |
1 to 10 of 17Source Open Targets
See all 17 diseasesTrials57
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02993406 | Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo | Phase 3 | 13,970 | 2024-01-03 | bempedoic acid | Its name | ClinicalTrials.gov |
| NCT02666664 | Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony) | Phase 3 | 2,230 | 2020-04-20 | bempedoic acid | Its name | ClinicalTrials.gov |
| NCT03067441 | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) | Phase 3 | 1,462 | 2020-12-22 | bempedoic acid | Its name | ClinicalTrials.gov |
| NCT02991118 | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk | Phase 3 | 779 | 2020-04-27 | bempedoic acid | Its name | ClinicalTrials.gov |
| NCT03337308 | A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy | Phase 3 | 382 | 2020-04-08 | bempedoic acid, bempedoic acid + ezetimibe fixed-dose combination | Its name | ClinicalTrials.gov |
| NCT02988115 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant | Phase 3 | 345 | 2020-04-03 | bempedoic acid | Its name | ClinicalTrials.gov |
| NCT03001076 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) | Phase 3 | 269 | 2020-04-03 | bempedoic acid | Its name | ClinicalTrials.gov |
| NCT03531905 | Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C | Phase 2 | 242 | 2020-04-09 | bempedoic acid | Its name | ClinicalTrials.gov |
| NCT04784442 | A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia | Phase 2 | 188 | 2024-03-04 | bempedoic acid | Its name | ClinicalTrials.gov |
| NCT01262638 | A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides | Phase 2 | 177 | 2021-03-16 | ETC-1002 | Its name | ClinicalTrials.gov |
1 to 10 of 57
See all 57 trialsComparisons in its trials34
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to Cardiovascular Death | 269 of 6,992 | 257 of 6,978 | 13,970 | NCT02993406 | Trial comparisons |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Myocardial Infarction | 261 of 6,992 | 334 of 6,978 | 13,970 | NCT02993406 | Trial comparisons |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to First Occurrence of Stroke | 135 of 6,992 | 158 of 6,978 | 13,970 | NCT02993406 | Trial comparisons |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Three Component MACE | 575 of 6,992 | 663 of 6,978 | 13,970 | NCT02993406 | Trial comparisons |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to All-cause Mortality | 434 of 6,992 | 420 of 6,978 | 13,970 | NCT02993406 | Trial comparisons |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE) | 819 of 6,992 | 927 of 6,978 | 13,970 | NCT02993406 | Trial comparisons |
| Bempedoic Acid 180 mg vs Placebo Comparator: Number of Participants With Time to First Occurrence of Coronary Revascularization | 435 of 6,992 | 529 of 6,978 | 13,970 | NCT02993406 | Trial comparisons |
| Bempedoic Acid 180 mg vs Placebo Comparator: deaths from any cause | 437 of 7,001 | 420 of 6,964 | 13,965 | NCT02993406 | Trial comparisons |
| Bempedoic Acid 180 mg vs Placebo Comparator: serious adverse events | 1,767 of 7,001 | 1,733 of 6,964 | 13,965 | NCT02993406 | Trial comparisons |
| Bempedoic Acid vs Placebo: deaths from any cause | 13 of 1,487 | 2 of 742 | 2,229 | NCT02666664 | Trial comparisons |
1 to 10 of 34
See all 34 comparisons in its trialsPapers from its trials31
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL3545313
GET https://conductscience.org/api/drugs/v1/CHEMBL3545313/trials?page=2